# Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients

> **NCT05762900** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 65 (estimated)

## Conditions studied

- Breast Cancer
- Radiotherapy Side Effect

## Interventions

- **RADIATION:** Ultra-fractionated radiation therapy

## Key facts

- **NCT ID:** NCT05762900
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-25
- **Primary completion:** 2025-10-25
- **Final completion:** 2030-10-25
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2023-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05762900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05762900, "Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05762900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*